Ardian and the Del Bono family renew their partnership in Neopharmed Gentili and welcome NB Renaissance as a new partner.
Ardian, a world-leading private investment firm, today announces its reinvestment through its latest fund in Neopharmed, together with NB Renaissance, jointly holding a majority stake with equal shares. Mediolanum Farmaceutici will maintain a significant stake in the Group.
Italian pharmaceutical group Mediolanum Farmaceutici and its CEO Alessandro Del Bono have renewed their partnership with Ardian as they look to continue the company's impressive growth after four years of strong performance. This includes defining further ambitious development projects for Neopharmed Gentili and welcoming Neuberger Berman as a new shareholder of the Group.
Under the agreement, Mediolanum Farmaceutici will retain a significant stake in Neopharmed Gentili and Alessandro Del Bono will continue to lead the company as Chief Executive Officer and Chairman of the Board.
Based in Milan, Neopharmed Gentili is one of the leading pharmaceutical companies operating in the Italian market. With one of the largest sales rep networks in Italy, Neopharmed Gentili is a market leader in therapeutic areas such as cardiovascular and neurology.
In partnership with Ardian, Neopharmed Gentili has pursued a long-term growth strategy, expanding both organically and through an ambitious buy-and-build plan, which resulted in six M&A deals in four years. This growth plan has also seen the Company strengthen and diversify its product portfolio, achieving revenues of 250 million euros.
Through the renewed agreement, the Del Bono family, Ardian and NB Renaissance have laid the foundation to continue to drive growth, supporting the company and its management team by providing fresh capital.
“We are very excited about the future. The partnership with Ardian and NB Renaissance represents an important step forward in the history of Neopharmed Gentili, which will ensure that it is increasingly competitive in a context of increasing complexity and will open new markets. We have achieved the goal of making Neopharmed Gentili a solid and credible player in the Italian pharmaceutical market thanks to the high scientific value of our solutions and the widely recognized quality of our team of professionals. Today we have new challenges and new goals and we look forward to being able to continue to grow and create value, always preserving our culture and identity". Alessandro DelBono, Chief Executive Officer and President – Neopharmed Gentili
“We are extremely proud of the relationship established with Alessandro Del Bono and with the entire management team of Neopharmed Gentili. Thanks to our partnership, the company has achieved brilliant results in the last four years, and we are convinced that there are numerous and continued growth opportunities in Italy and abroad. We believe this partnership with NB Renaissance will facilitate further international consolidation and development, while safeguarding the current corporate culture." Nicolò Saidelli, Member of the Executive Committee, Head of Ardian Italia and Deputy Head of Buyout - Ardian
“We are very grateful that the Del Bono family and Ardian have chosen NB Renaissance as their new partner and we feel a strong responsibility to support the growth, development and value creation of Neopharmed. Based on our long-standing experience in the pharmaceutical industry, we believe we can make a significant contribution to the success of the company and its stakeholders." Fabio Canè, Co-Founder and Senior Partner – NB Renaissance
Related news: Italian pharmaceutical company, Neopharmed Gentili acquires Valeas
Milan, Valeas workers in the square: "No to unfair collective dismissal" Editor's note
